Global health and economy are deeply influenced by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and its newly emerging variants. Nanobodies with nanometer …

As the world continues to grapple with infectious diseases, scientists are constantly
searching for effective ways to combat these deadly pathogens. One promising avenue of …

Liposomes composed of sulfated lactosyl archaeol (SLA) have been shown to be a safe and
effective vaccine adjuvant with a multitude of antigens in preclinical studies. In particular …

Since SARS-CoV-2 was first reported in late 2019, multiple variations of the original virus
have emerged. Each variant harbors accumulations of mutations, particularly within the …

The COVID-19 pandemic and SARS-CoV-2 variants have dramatically illustrated the need
for a better understanding of antigen (epitope)-antibody (paratope) interactions. To gain …

Acinetobacter baumannii is a Gram-negative bacterial pathogen that exhibits high intrinsic
resistance to antimicrobials, with treatment often requiring the use of last-resort antibiotics …

SARS-CoV-2 subunit vaccines continue to be the focus of intense clinical development
worldwide. Protein antigens in these vaccines most commonly consist of the spike …

Nanobodies, single-domain antibodies derived from variable domain of camelid or shark
heavy-chain antibodies, have unique properties with small size, strong binding affinity, easy …

In this work, we developed llama-derived nanobodies (Nbs) directed to the receptor binding
domain (RBD) and other domains of the Spike (S) protein of SARS-CoV-2. Nanobodies …

The global impact of zoonotic viral outbreaks underscores the pressing need for innovative
antiviral strategies, particularly against respiratory zoonotic RNA viruses. These viruses …